Illinois' innovation to change how scientists treat MRSA
from BusinessWire via Morningstar
Startup company ImmuVen and the University of Illinois Urbana-Champaign have entered into a license agreement under which ImmuVen will develop modified T cell receptor proteins for the purpose of treating cancer and methicillin-resistant Staphylococcus aureus (MRSA). ImmuVen was co-founded by David Kranz, Ph.D., of the University of Illinois Urbana-Champaign and Patrick Schlievert, Ph.D., of the University of Minnesota.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063